Analysts' Actions: AAPL, INTC, GS, BAC, YHOO

NEW YORK ( TheStreet) -- CHANGE IN RATINGS, EPS

Alpha Natural ( ANR) rated new Buy at Sterne AgeeANR was initiated with a Buy rating, Sterne Agee said. $35 price target. Company remains leveraged to growth in the met coal market.

Apple ( AAPL) estimates, target increased at Morgan Stanley.AAPL estimates were raised through 2013. iPhone continues to drive growth. Overweight rating and new $480 price target.

Apple estimates increased at UBS.AAPL estimates raised through 2013. iPhone purchase and carrier launch delays ahead of 4S cause shortfall. Maintain $510 price target and Buy rating.

Arch Coal ( ACI) rated new Neutral at Sterne Agee. $23 price target. Company faces integration challenges.

Bank of America ( BAC) estimates lowered at Sterne Agee.BAC estimates were cut through 2013. Company will take a while to turn its business around. Neutral rating and $7 price target.

Bank of America numbers lowered at UBS. Shares of BAC now seen reaching $7. Estimates also lowered on weaker capital markets and lower reserve releases. Neutral rating.

Chipotle Mexican Grill ( CMG) rated new Neutral at UBS. $345 price target. Solid near term outlook, but appears appropriately valued.

Citrix Systems ( CTXS) upgraded at Needham from Hold to Buy. $85 price target. Spending on data center projects should remain strong.

Coca-Cola ( KO) estimates lowered at Credit Suisse through 2013. Currency changes are cutting into earnings. Outperform rating and $95 price target.

Coca-Cola numbers lowered at UBS. Shares of KO now seen reaching $73. Estimates also lowered on currency and spending impact. Maintain Buy rating.

Cree ( CREE) estimates, target reduced at Sterne Agee. Shares of CREE now seen reaching $52. Estimates also cut, to match the company's new guidance. Buy rating.

Cree estimates, target lowered at UBS.Shares of CREE now seen reaching $29.50. Estimates also lowered as outlook suggest industry is still bottoming. Neutral rating.

EMC ( EMC) estimates upped at Sterne Agee through 2012. Company is gaining market share and realizing higher margins. Buy rating and $30 price target.

Forest Laboratories ( FRX) numbers reduced at Goldman.Shares of FRX now seen reaching $30. Estimates also cut, given the company's negative operating leverage.

Forest Labs estimates, target cut at UBS.Shares of FRX now seen reaching $32. Estimates also lowered on below guidance launches. Neutral rating.

Fossil ( FOSL) rated new Buy at Citigroup. $114 price target. Strategic positions and minimal competition have yielded moderately priced watch market leadership.

Goldman Sachs ( GS) estimates reduced at ThinkEquity through 2012. Company will likely continue to see lower capital markets activity. Outperform rating and $181 price target.

Goldman Sachs estimates, target cut at UBS. Shares of GS now seen reaching $140. Estimates also lowered on weaker expectations of capital markets activity. Buy rating.

Grainger ( GWW) estimates, target raised at UBS.Shares of GWW now seen reaching $177. Estimates also increased on solid inflation management and growth initiatives gaining. Neutral rating.

Harley-Davidson ( HOG) numbers cut at Goldman.Shares of HOG now seen reaching $44. Estimates also reduced, given higher operating costs. Neutral rating.

Harley-Davidson estimates cut at UBS through 2012. Q3 margins miss and FY11 margin guidance revised down. Maintain $39 price target and Neutral rating.

Hospira ( HOSP) estimates, target cut at Citigroup.Shares of HOSP now seen reaching $30. Estimates also lowered on manufacturing issus at the Rocky Mount facility. Neutral rating.

Human Genome ( HGSI) numbers cut at ThinkEquity.Shares of HGSI now seen reaching $26. Estimates also reduced, given a modest Benlysta launch. Buy rating.

Intel ( INTC) estimates, target raised at Citigroup.Shares of INTC now seen reaching $27.50. Estimates also increased as company is executing well, but market disparity a lingering concern. Buy rating.

Intel estimates, target raised at Goldman. Shares of INTC now seen reaching $22. Estimates also increased, as higher sales is driving margin expansion.

Intel estimates, target raised at UBS. Shares of INTC now seen reaching $30. Estimates also increased as solid execution offsets macro weakness. Buy rating.

Intuitive Surgical ( ISRG) numbers boosted at Goldman.Shares of ISRG now seen reaching $412. Estimates also upped, to match the company's new guidance. Neutral rating.

Juniper ( JNPR) estimates, target cut at Credit Suisse.Shares of JNPR now seen reaching $25. Estimates also reduced, given the company's new guidance. Neutral rating.

Juniper Networks estimates lowered at UBS through 2012. Strong 3Q bookings and visibility better into 1Q, but still risk. Maintain $24 price target and Neutral rating.

Juniper Networks downgraded at Wells from Outperform to Market Perform. Growth outlook is deteriorating.

Netflix ( NFLX) estimates reduced at Credit Suisse.NFLX estimates were cut through 2013. Company is realizing slower domestic subscriber growth. Outperform rating and $240 price target.

Parker Hannifin ( PH) numbers raised at Goldman.Shares of PH now seen reaching $81. Estimates also increased, given better business momentum. Neutral rating.

Rightnow Technologies ( RNOW) downgraded at Stifel from Buy to Hold. Valuation call.

Sotheby's ( BID) rated new Neutral at Citigroup. $35 price target. High trust agency model with low inventory risk.

State Street ( STT) numbers increased at Goldman.STT estimates were raised through 2013. Company is gaining market share and keeping a tight lid on costs. Buy rating and new $48 price target.

Steel Dynamics ( STLD) numbers lowered at Jefferies.STLD estimates were cut through 2012. Company is leveraged to lower steel demand. Buy rating and new $16 price target.

Steven Madden ( SHOO) rated new Buy at Citigroup. $41 price target. Accelerating sales/EPS despite economy.

Under Armour ( UA) numbers raised at Jefferies.Shares of UA now seen reaching $73. Estimates also increased, as the company should continue to expand margins. Buy rating.

UnitedHealth ( UNH) estimates increased at Credit Suisse.UNH estimates were raised through 2012. Company continues to deliver solid growth. Outperform rating and $72 price target.

UnitedHealth estimates raised at UBS through 2011. Among best positioned to navigate uncertainties heading into 2014. Maintain $58 price target and Buy rating.

US Steel ( X) rated new Market Perform at Wells Fargo. Company continues to face macro headwinds.

Union Drilling ( UDRL) downgraded to sell at TheStreet Ratings.

Vera Bradley ( VRA) rated new Buy at Citigroup. $51 price target. See sales upside on industry leading comparable same store sales.

VF Corp. ( VFC) estimates raised at UBS through 2012. TBL, FX, and North Face upside. Maintain $135 price target and Buy rating.

Whole Foods ( WFM) upgraded at Jefferies to Buy. $90 price target. Estimates also boosted, as the company continues to deliver comp sales growth.

WW Grainger ( GWW) numbers upped at Goldman.GWW estimates were boosted through 2013. Company is realizing higher margins. Neutral rating and new $176 price target.

Yahoo! ( YHOO) estimates upped at Credit Suisse through 2012. Company is realizing higher margins. Neutral rating and $19 price target.

Yahoo! estimates increased at UBS through 2012. Mixed quarter as investors remain focused on potential event. Maintain $16 price target and Neutral rating.

Zygo ( ZIGO) upgraded to buy at TheStreet Ratings.

Related links:


This article was written by a staff member of TheStreet.

More from Stocks

Spotlight On Space Exploration as Jeff Bezos' Blue Origin Sets Ticket Sale Date

Spotlight On Space Exploration as Jeff Bezos' Blue Origin Sets Ticket Sale Date

This Will Be the Ultimate Buy (or Sell) Signal for Stocks

This Will Be the Ultimate Buy (or Sell) Signal for Stocks

3 Fierce Chinese Tech Stocks to Gamble on Right Now

3 Fierce Chinese Tech Stocks to Gamble on Right Now

Stocks Slammed on Latest Trump Tariff Fears

Stocks Slammed on Latest Trump Tariff Fears

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War